BACKGROUND: Otherwise healthy persons with a small number of B-cell clones circulating in the peripheral blood have been designated as having monoclonal B-cell lymphocytosis (MBL). Hospital-based series indicate an excess risk of progression from MBL to chronic lymphocytic leukemia (CLL). In this prospective cohort study, we tested the hypothesis that CLL is always preceded by MBL. METHODS: Among 77,469 healthy adults who were enrolled in the nationwide, population-based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, we identified 45 subjects in whom CLL was subsequently diagnosed (up to 6.4 years later) through the collection of a peripheral-blood sample. Using six-color flow cytometry (with antibodies CD45, CD19, CD5, CD10, kappa, and lambda) and immunoglobulin heavy-chain gene rearrangement by reverse-transcriptase-polymerase-chain-reaction assay, we determined the association between MBL and subsequent CLL and characterized the immunoglobulin gene repertoire of the prediagnostic B-cell clones. RESULTS: On the basis of either flow-cytometric or molecular analysis, 44 of 45 patients with CLL (98%; 95% confidence interval [CI], 88 to 100) had a prediagnostic B-cell clone; in 41 patients (91%; 95% CI, 79 to 98), the presence of the B-cell clone was confirmed by both methods. The presence of immunoglobulin heavy-chain variable (IGHV) genes was determined in 35 of 45 prediagnostic clones (78%). Of these clones, 16 (46%) were IGHV3 subgroup genes (including 6 [17%] IGHV3-23 genes) and 9 (26%) were IGHV4 subgroup genes (including 4 [11%] IGHV4-34 genes). Furthermore, 27 of 35 of the IGHV sequences (77%) had mutations, with similar distributions after stratification either below or above the median time between the collection of the prediagnostic blood sample and the subsequent CLL diagnosis. CONCLUSIONS: In peripheral blood obtained up to 77 months before a CLL diagnosis, prediagnostic B-cell clones were present in 44 of 45 patients with CLL. 2009 Massachusetts Medical Society
BACKGROUND: Otherwise healthy persons with a small number of B-cell clones circulating in the peripheral blood have been designated as having monoclonal B-cell lymphocytosis (MBL). Hospital-based series indicate an excess risk of progression from MBL to chronic lymphocytic leukemia (CLL). In this prospective cohort study, we tested the hypothesis that CLL is always preceded by MBL. METHODS: Among 77,469 healthy adults who were enrolled in the nationwide, population-based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, we identified 45 subjects in whom CLL was subsequently diagnosed (up to 6.4 years later) through the collection of a peripheral-blood sample. Using six-color flow cytometry (with antibodies CD45, CD19, CD5, CD10, kappa, and lambda) and immunoglobulin heavy-chain gene rearrangement by reverse-transcriptase-polymerase-chain-reaction assay, we determined the association between MBL and subsequent CLL and characterized the immunoglobulin gene repertoire of the prediagnostic B-cell clones. RESULTS: On the basis of either flow-cytometric or molecular analysis, 44 of 45 patients with CLL (98%; 95% confidence interval [CI], 88 to 100) had a prediagnostic B-cell clone; in 41 patients (91%; 95% CI, 79 to 98), the presence of the B-cell clone was confirmed by both methods. The presence of immunoglobulin heavy-chain variable (IGHV) genes was determined in 35 of 45 prediagnostic clones (78%). Of these clones, 16 (46%) were IGHV3 subgroup genes (including 6 [17%] IGHV3-23 genes) and 9 (26%) were IGHV4 subgroup genes (including 4 [11%] IGHV4-34 genes). Furthermore, 27 of 35 of the IGHV sequences (77%) had mutations, with similar distributions after stratification either below or above the median time between the collection of the prediagnostic blood sample and the subsequent CLL diagnosis. CONCLUSIONS: In peripheral blood obtained up to 77 months before a CLL diagnosis, prediagnostic B-cell clones were present in 44 of 45 patients with CLL. 2009 Massachusetts Medical Society
Authors: Lynn R Goldin; Magnus Björkholm; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren Journal: Haematologica Date: 2009-03-13 Impact factor: 9.941
Authors: A Carbone; A Gloghini; G Gaidano; S Franceschi; D Capello; H G Drexler; B Falini; R Dalla-Favera Journal: Blood Date: 1998-10-01 Impact factor: 22.113
Authors: J L Garnier; Y Lebranchu; N Lefrançois; X Martin; J M Dubernard; F Berger; J L Touraine Journal: Transplant Proc Date: 1995-04 Impact factor: 1.066
Authors: Richard B Hayes; Alice Sigurdson; Lee Moore; Ulrike Peters; Wen-Yi Huang; Paul Pinsky; Douglas Reding; Edward P Gelmann; Nat Rothman; Ruth M Pfeiffer; Robert N Hoover; Christine D Berg Journal: Mutat Res Date: 2005-07-27 Impact factor: 2.433
Authors: R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi Journal: Blood Date: 1999-09-15 Impact factor: 22.113
Authors: Krzysztof Jamroziak; Ewa Balcerczak; Piotr Smolewski; Robert W Robey; Barbara Cebula; Mariusz Panczyk; Monika Kowalczyk; Anna Szmigielska-Kapłon; Marek Mirowski; Susan E Bates; Tadeusz Robak Journal: Pharmacol Rep Date: 2006 Sep-Oct Impact factor: 3.024
Authors: Lynn R Goldin; Mark C Lanasa; Susan L Slager; James R Cerhan; Celine M Vachon; Sara S Strom; Nicola J Camp; Logan G Spector; Jose F Leis; Vicki A Morrison; Martha Glenn; Kari G Rabe; Sara J Achenbach; Sallie D Algood; Fatima Abbasi; Laura Fontaine; Michelle Yau; Laura Z Rassenti; Neil E Kay; Timothy G Call; Curtis A Hanson; J Brice Weinberg; Gerald E Marti; Neil E Caporaso Journal: Br J Haematol Date: 2010-08-25 Impact factor: 6.998
Authors: Youn K Shim; Dannie C Middleton; Neil E Caporaso; Jane M Rachel; Ola Landgren; Fatima Abbasi; Elizabeth S Raveche; Andy C Rawstron; Alberto Orfao; Gerald E Marti; Robert F Vogt Journal: Cytometry B Clin Cytom Date: 2010 Impact factor: 3.058
Authors: Brian A McCarthy; Sophia Yancopoulos; Mike Tipping; Xiao-Jie Yan; Xue Ping Wang; Fiona Bennett; Wentian Li; Martin Lesser; Santanu Paul; Erin Boyle; Carolina Moreno; Rosa Catera; Bradley T Messmer; Giovanna Cutrona; Manlio Ferrarini; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Andrew C Rawstron; Nicholas Chiorazzi Journal: Immunol Res Date: 2015-12 Impact factor: 2.829
Authors: M Chadeau-Hyam; R C H Vermeulen; D G A J Hebels; R Castagné; G Campanella; L Portengen; R S Kelly; I A Bergdahl; B Melin; G Hallmans; D Palli; V Krogh; R Tumino; C Sacerdote; S Panico; T M C M de Kok; M T Smith; J C S Kleinjans; P Vineis; S A Kyrtopoulos Journal: Ann Oncol Date: 2014-02-20 Impact factor: 32.976
Authors: Neil E Caporaso; Gerald E Marti; Robert F Vogt; Youn K Shim; Dan Middleton; Ola Landgren Journal: Cytometry B Clin Cytom Date: 2010-01 Impact factor: 3.058
Authors: Shih-Shih Chen; Mara H Sherman; Erin Hertlein; Amy J Johnson; Michael A Teitell; John C Byrd; Christoph Plass Journal: Cell Cycle Date: 2009-11-15 Impact factor: 4.534